{"title":"Clinical utility of incorporating next-generation sequencing results in the management algorithm of pancreatic cysts","authors":"Alex R. Jones MD , Olgert Bardhi MD , Patricio Polanco MD , Daniel Ellis MD , Christofer Bishop BSN, RN, OCN , Veronica Coleman BSN, RN, OCN , Blake Foley MPAS, PA-C , Gaurav Khatri MD , Markus Goldschmiedt MD , John Mansour MD , Hendrikus Vanderveldt MD , Aatur Singhi MD, PhD , Nisa Kubiliun MD , Tarek Sawas MD, MPH","doi":"10.1016/j.gie.2025.01.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and Aims</h3><div>Pancreatic cysts often pose challenges in predicting malignant progression. Next-generation sequencing (NGS) has become an appealing ancillary diagnostic test. The diagnostic performance is well characterized, but the impact on clinical management remains unclear. We evaluated the efficacy of integrating NGS into cyst management algorithms.</div></div><div><h3>Methods</h3><div>This single-center retrospective study included 441 adult patients who were seen at our high-risk pancreatic lesion clinic between 2016 and 2022 and had NGS data available. Performance characteristics of PancreaSeq (University of Pittsburgh Medical Center, Pittsburgh, Pa, USA) were calculated. The clinical utility of PancreaSeq in guiding surgical management and differentiating cyst type was evaluated.</div></div><div><h3>Results</h3><div>Twenty-five high-risk mutations demonstrated a sensitivity of 72.7% (95% confidence interval [CI], 49.8-89.3), a specificity of 97.8% (95% CI, 96-99), and an area under the receiver-operating characteristic curve of .85 (95% CI, .76-.95) in predicting advanced neoplasia. NGS detected <em>KRAS</em> or <em>GNAS</em> mutations in 179 of 324 patients (55.3%) and <em>VHL</em> mutations in 15 of 324 patients (3.4%) with unclear cyst types, facilitating the decision regarding surveillance versus clinic discharge. Among 27 patients with isolated pancreatic duct dilation, 12 (48.1%) had mutations consistent with mucinous neoplasms leading to a diagnosis of main duct intraductal papillary mucinous neoplasm. These findings resulted in surgical management for 6 patients. Overall, 115 of 441 patients (26.1%) had some management change after undergoing NGS.</div></div><div><h3>Conclusions</h3><div>NGS informed surgical decision-making, cyst type differentiation, and evaluation of pancreatic duct dilation, leading to changes in management. Indeed, NGS emerged as a useful tool in select patients with pancreatic lesions by improving diagnostic precision and guiding patient care paths.</div></div>","PeriodicalId":12542,"journal":{"name":"Gastrointestinal endoscopy","volume":"102 2","pages":"Pages 223-232.e3"},"PeriodicalIF":7.5000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastrointestinal endoscopy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0016510725000100","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/14 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and Aims
Pancreatic cysts often pose challenges in predicting malignant progression. Next-generation sequencing (NGS) has become an appealing ancillary diagnostic test. The diagnostic performance is well characterized, but the impact on clinical management remains unclear. We evaluated the efficacy of integrating NGS into cyst management algorithms.
Methods
This single-center retrospective study included 441 adult patients who were seen at our high-risk pancreatic lesion clinic between 2016 and 2022 and had NGS data available. Performance characteristics of PancreaSeq (University of Pittsburgh Medical Center, Pittsburgh, Pa, USA) were calculated. The clinical utility of PancreaSeq in guiding surgical management and differentiating cyst type was evaluated.
Results
Twenty-five high-risk mutations demonstrated a sensitivity of 72.7% (95% confidence interval [CI], 49.8-89.3), a specificity of 97.8% (95% CI, 96-99), and an area under the receiver-operating characteristic curve of .85 (95% CI, .76-.95) in predicting advanced neoplasia. NGS detected KRAS or GNAS mutations in 179 of 324 patients (55.3%) and VHL mutations in 15 of 324 patients (3.4%) with unclear cyst types, facilitating the decision regarding surveillance versus clinic discharge. Among 27 patients with isolated pancreatic duct dilation, 12 (48.1%) had mutations consistent with mucinous neoplasms leading to a diagnosis of main duct intraductal papillary mucinous neoplasm. These findings resulted in surgical management for 6 patients. Overall, 115 of 441 patients (26.1%) had some management change after undergoing NGS.
Conclusions
NGS informed surgical decision-making, cyst type differentiation, and evaluation of pancreatic duct dilation, leading to changes in management. Indeed, NGS emerged as a useful tool in select patients with pancreatic lesions by improving diagnostic precision and guiding patient care paths.
期刊介绍:
Gastrointestinal Endoscopy is a journal publishing original, peer-reviewed articles on endoscopic procedures for studying, diagnosing, and treating digestive diseases. It covers outcomes research, prospective studies, and controlled trials of new endoscopic instruments and treatment methods. The online features include full-text articles, video and audio clips, and MEDLINE links. The journal serves as an international forum for the latest developments in the specialty, offering challenging reports from authorities worldwide. It also publishes abstracts of significant articles from other clinical publications, accompanied by expert commentaries.